Investors

About

Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.

The company is developing three small molecule products: lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis. IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, and castration-resistant prostate cancer. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Stock Quote
NASDAQIMUX
Fast Facts
  •  Company Founded in 2016
  •  3 Development Programs
  •  Headquartered in New York City
  •  NASDAQ: IMUX
  •  Experts in Selective Oral Drugs in Immunology
Latest News
Nov 17, 2022

– Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worsening – – Virtual Multiple Sclerosis R&D Day to be Held Today, November 17, 2022...

Nov 10, 2022

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune...

Nov 3, 2022

– $72.8 Million in Cash and Cash Equivalents as of September 30, 2022, Plus $56.4 Million of Net Cash Raised in October 2022 Expected to Fund Immunic Into the Fourth Quarter of 2024 – –...

View All

Contact Us

Immunic Therapeutics
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Rx Communications
Paula Schwartz
Managing Director
+1 917 322 2216
immunic@rxir.com

Subscribe
To receive all investor alerts please subscribe here
* Required Fields